ASH 2024 | A study of brentuximab vedotin, nivolumab, and ipilimumab in pediatric patients with R/R cHL

Yes, so these are the pediatric colleagues who participated in the intergroup study of brentuximab vedotin, which is an antibody drug conjugate to CD30, and the checkpoint inhibitors nivolumab and ipilimumab in Hodgkin lymphoma. This was the study that I led and I presented the data at ASH last year for the Phase II that was randomized between BV-nivo and ipi-nevo, showing that there was no difference in the CR rate between the two arms, and that there was no difference in the progression-free survival at the follow-up that we did. We subsequently presented data at Cologne, where we showed that for the patients who did not go to transplant, so the patients who opted not to go to transplant, there was a significant improvement in progression-free survival in the triplet arm of brentuximab, ipi, and nivo compared to brentuximab and nivo. These are the pediatric patients who were on this study presented by the pediatric group, and these were a small number of patients. But what they showed, patients were equally randomized to each arm, and what they showed is that patients in both arms had 100% complete response rate, which is very encouraging, but that a complete response did not equal a durable full response because there was a substantial difference in the progression-free survival for patients who got brentuximab-nivo versus brentuximab-ipi-nivo with a significant improvement in progression-free survival for patients who got the triplet compared to the doublet. So what this means and where this is going, it’s a small number of patients, but it’s intriguing.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.